PURPOSE: This retrospective case series aimed to document healthcare providers' (HCPs) real-world experience of using the enVista ENVY (EN) and enVista ENVY toric (ETN) full visual range intraocular lenses (IOLs). This interim sub-analysis reports visual acuity outcomes with EN, stratified by residual refractive error.

METHODS: This interim sub-analysis of a retrospective, multicenter, cross-sectional study includes case report forms (CRFs) from 14 HCPs from the USA (n=12) and Canada (n=2). HCPs provided on-label EN/ETN electronic medical record cases using a standardized CRF to document real-world clinical performance. Key outcome measures included monocular vision outcomes (uncorrected distance VA [UDVA], corrected distance VA [CDVA], uncorrected intermediate VA [UIVA], uncorrected near VA [UNVA]), manifest refraction spherical equivalent (MRSE) and residual cylinder. Outcomes were stratified by residual refractive error (sphere, cylinder, and MRSE) in 0.25 D groups. Patients were followed for ≥6 months.

RESULTS: Eyes implanted with the EN IOL and residual sphere of -0.5 D achieved ≤20/25 UDVA, UIVA and UNVA in 25%, 100% and 100%, respectively. With a residual sphere of -0.25 D, ≤20/25 UDVA, UIVA and UNVA was achieved in 57%, 100% and 71%, respectively, and with a residual sphere of 0.00 D ≤20/25 UDVA, UIVA and UNVA was achieved in 70%, 71% and 44%, respectively. Eyes with a residual sphere of ≥+0.25 D achieved ≤20/25 UDVA, UIVA and UNVA in more than 80%, more than 82%, and more than 76%, respectively.

CONCLUSION: In this retrospective case series, the EN IOL provided good distance, intermediate, and near visual acuity for the majority of patients. Plano to hyperopic outcomes may lead to the best UDVA.